Our analysis identified nine candidates (Figs. 3e and 5b, c) that were significantly differentially expressed across all three datasets, including seven novel candidates, as being involved in drug resistance in HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.